Post-Surgical Recovery Protocol for dogs
Also searched as: after surgery peptide protocol, orthopaedic recovery stack
The short answer
A conservative sequence built around BPC-157, intended to support a surgeon's plan rather than compete with it.
What it is and why these compounds
This is the most defensible application on the site and the one with the lowest risk of doing harm, provided it stays subordinate to the surgical plan. It centres on BPC-157 — the compound with published canine pharmacokinetic and safety data and no cancer contraindication — with GHK-Cu applied topically to the incision. TB-500 is included only where cancer has been definitively excluded. The single most important point is that nothing here justifies an early return to activity: enforced rest and structured rehabilitation determine the outcome, and a dog that feels better sooner is a dog more likely to damage the repair.
Compounds in this protocol
The only peptide on this site with published canine pharmacokinetic data.
A copper-binding tripeptide with a published canine wound-healing study.
The most established compound in veterinary research, with equine work dating to the early 2000s.
Before starting
These are the decisions that determine whether this protocol is appropriate at all.
⚠ Read first
Nothing in this protocol justifies deviating from the surgeon's activity restrictions. Improved comfort is not evidence of a healed repair.
Caution
A fresh surgical incision should not have anything applied to it without the surgeon's agreement.
Caution
TB-500 should be omitted entirely unless malignancy has been excluded, which is particularly relevant in older dogs having masses removed.
Example timeline
A representative schedule drawn from the published literature, showing what is monitored and when. Any actual protocol should be set by the veterinarian managing the case.
- 1Days 1–14Early healing
What owners observe
Follow the surgeon's activity restrictions exactly. Apply topical GHK-Cu around, not on, a fresh closed incision unless your veterinarian directs otherwise. Begin BPC-157 daily.
Clinical monitoring
Baseline bloodwork. BPC-157 at the weight-appropriate dose daily. Monitor the incision for dehiscence, discharge, or heat at every check.
- 2Weeks 2–6Tissue repair
What owners observe
Improved weight bearing and comfort. This is precisely when owners are most tempted to relax restrictions, and precisely when doing so causes the most failures.
Clinical monitoring
Continue BPC-157. Begin structured physiotherapy per the surgeon's protocol. Reassess gait score. Consider adding TB-500 only if cancer status is confirmed clear.
- 3Weeks 6–12Return to function
What owners observe
Graduated return to activity strictly on the surgeon's schedule. Rehabilitation exercises do more for the final outcome at this stage than any compound.
Clinical monitoring
Taper BPC-157. Follow-up imaging to confirm repair. Discontinue topical GHK-Cu once the incision has fully matured.
Investigated for
Post-surgical recovery
Supporting tissue repair, comfort, and return to function after an orthopaedic or soft tissue procedure.
Cranial cruciate ligament (CCL) tear
Rupture of the stabilising ligament in the stifle, the single most common orthopaedic injury in dogs.
Wound healing
Repair of surgical incisions, lacerations, ulcers, and chronic non-healing wounds.
Common questions
What is the Post-Surgical Recovery Protocol for dogs?+
A conservative sequence built around BPC-157, intended to support a surgeon's plan rather than compete with it. It combines BPC-157, GHK-Cu, TB-500.
Is the Post-Surgical Recovery Protocol safe for dogs?+
Nothing in this protocol justifies deviating from the surgeon's activity restrictions. Improved comfort is not evidence of a healed repair. A fresh surgical incision should not have anything applied to it without the surgeon's agreement. TB-500 should be omitted entirely unless malignancy has been excluded, which is particularly relevant in older dogs having masses removed.
How long does the Post-Surgical Recovery Protocol run?+
The example timeline runs from days 1–14 through weeks 6–12. Actual duration should be set by the veterinarian managing the case and adjusted on response.
References
- 1.CANINE STUDYHe L, et al. Pharmacokinetics, distribution, metabolism and excretion of BPC 157 in rats and dogs. Frontiers in Pharmacology, 2022. PMID 36588722
- 2.CANINE STUDYXu C, et al. Preclinical safety evaluation of body protective compound-157. Regulatory Toxicology and Pharmacology, 2020. PMID 32334036
- 3.Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine. Orthopaedic Journal of Sports Medicine, 2025. PMC12313605
- 4.Gwyer D, Wragg NM, Wilson SL Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019. PMID 30915550
- 5.Jozwiak M, et al. Multifunctionality of BPC 157: Literature and Patent Review. Pharmaceuticals, 2025. PMC11859134
- 6.CANINE STUDYJournal of the American Holistic Veterinary Medical Association Case report: canine stifle injury managed with BPC-157 and TB-500. JAHVM, 2023. View source
- 7.CANINE STUDYCanapp SO, et al. The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Veterinary Surgery, 2003. PMID 14569578
- 8.Maquart FX, et al. In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex in rat experimental wounds. Journal of Clinical Investigation, 1993. PMID 8227350
- 9.Pickart L, Vasquez-Soltero JM, Margolina A GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International, 2015. PMC4508379
- 10.Pickart L, Margolina A Regenerative and Protective Actions of the GHK-Cu Peptide. International Journal of Molecular Sciences, 2018. PMC6073405
- 11.Kleinman HK, Sosne G Thymosin beta 4 promotes dermal healing: animal studies. Annals of the New York Academy of Sciences, 2010. PMID 20536453
- 12.Goldstein AL, Hannappel E, Sosne G, Kleinman HK Thymosin beta-4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy, 2012. PMID 22074294
- 13.Kwok WH, et al. Doping control analysis of TB-500 in equine urine and plasma. Journal of Chromatography B, 2013. PMID 23084823
- 14.Esposito S, et al. TB500/TB1000: understanding misbranded drugs. Drug Testing and Analysis, 2022. View source
Where to source research peptides
Compound quality is the variable most owners underestimate. Purity, accurate peptide content, and correct labelling determine whether any published dosing figure means anything at all. Pet & Peps Research publishes third-party testing on the compounds covered in this guide and supports this site.
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.